How a Small Water Glass Bottle Can Disrupt an Entire Vaccine Supply Chain

In vaccine manufacturing, disruptions are not always caused by complex biologics or expensive APIs. Sometimes, a small glass bottle filled with sterile water can become the biggest bottleneck in the entire supply chain.

During my time in vaccine procurement and planning, one such product taught me how even a low-cost component can determine whether life-saving vaccines reach patients on time.

That product was the diluent.

Diluent is essentially Water for Injection (WFI) supplied along with lyophilized (freeze-dried) vaccines such as BCG, MMR, and Rotavirus vaccines. Before administration, the vaccine has to be reconstituted using this diluent.

From a commercial standpoint, diluent may not be a value-creating product. However, operationally, it is highly critical because a vaccine batch cannot be dispatched without it.

Why Diluent Manufacturing Is Usually Outsourced

Unlike vaccines, diluent manufacturing does not justify heavy investment in dedicated internal infrastructure. The process requires sterile filling lines, validation systems, GMP-compliant operations, microbiological controls, and regulatory documentation — all of which are expensive to maintain for a relatively low-margin product.

As a result, most pharmaceutical companies subcontract diluent manufacturing to specialized sterile manufacturing vendors.

However, outsourcing in pharmaceuticals is not as simple as transferring production to a third party.

If the final vaccine is supplied to regulated markets such as the US or Europe, the subcontracting facility must also comply with the same regulatory expectations as the parent company. This includes:

• GMP (Good Manufacturing Practices) compliance

• Regulatory audits from agencies such as USFDA, MHRA, WHO-GMP, or EMA

• Sterility assurance validation

• Media fill validations

• Environmental monitoring compliance

• Data integrity controls

• Batch traceability systems

• Quality Management System (QMS) adherence

In pharmaceutical supply chains, the compliance risk of a subcontractor becomes the compliance risk of the manufacturer itself.

The Subcontracting Model

Our operating model was similar to a conversion-based subcontracting arrangement.

We supplied the subcontracting vendor with:

• APIs/raw materials

• Glass bottles

• Rubber stoppers

• Cartons and packaging materials

• Artwork components

The vendor handled sterile filling, sealing, sterilization processes, inspection, and batch execution. In return, they charged us conversion costs.

Since this was a strategic partnership, we had:

• one dedicated filling line reserved for us,

• and additional shared capacity of approximately seven production days per month from another line.

This ensured continuity of supply while also giving flexibility during demand spikes.

The Planning Complexity Behind “Just Water”

Planning for diluent was far more complex than it appeared.

Our planning cycle worked on an M0 for M1 model:

• M0 = Current planning month

• M1 = Next execution month

For example, plans finalized in April (M0) would drive manufacturing execution for May (M1).

The demand signal originated from the vaccine S&OP (Sales & Operations Planning) process. Since every lyophilized vaccine required a corresponding diluent unit, we aligned diluent production with vaccine filling plans while also adjusting for:

• Reorder Levels (ROLs)

• Safety stock requirements

• Batch expiry risks

• Vendor capacity constraints

An additional business layer complicated planning further.

Senior management had mandated procurement commitments toward this subcontracting vendor because the company also had strategic equity participation in the facility. This meant planning decisions were not driven purely by operational demand but also by strategic sourcing obligations.

The challenge was balancing:

• minimum procurement commitments,

• inventory holding risk,

• and expiry management.

Overproduction could result in inventory write-offs. Underproduction could stop vaccine dispatches entirely.

Managing Volatile Export Market Demand

One of the most challenging areas was handling export-market-specific diluents.

Certain regulated markets required different artworks, labels, and packaging configurations. These demands were highly volatile and often urgent.

To reduce lead time, we introduced a semi-finished inventory strategy.

We maintained a stock of:

• filled,

• sterilized,

• but unlabeled diluent units.

This unlabeled inventory could be stored for a maximum defined holding period. If no export demand materialized within that window, the stock would be converted into regular domestic-market diluent.

However, if urgent export demand arrived, we only needed to align:

• artwork development,

• packaging material procurement,

• carton availability,

• and labeling execution.

By decoupling sterile filling from artwork readiness, we were able to reduce supply lead time by nearly 15 days.

In vaccine supply chains, those 15 days can determine whether a market faces stock availability or stockout.

The Hidden Supply Chain Risk

The biggest learning for me was this:

Even if vaccine batches are fully manufactured, quality approved, and ready for dispatch, they still cannot move to market if the associated diluent is unavailable.

A low-cost component can hold up an entire high-value vaccine supply chain.

And the risks were real:

• vendor maintenance shutdowns,

• audit observations,

• artwork delays,

• packaging shortages,

• sterilization schedule slippages,

• or poor planning assumptions.

Any one of these could delay vaccine dispatch timelines.

Final Reflection

Supply chains are often judged by the value of the product being managed. But in reality, supply chains are governed by dependency management.

Sometimes the smallest product in the network creates the biggest operational impact.

Managing diluent planning taught me that effective supply chain management is not just about procurement or production. It is about synchronizing planning, regulatory compliance, vendor strategy, inventory risk, and cross-functional execution — often around products most people would overlook.